advanced search

Welcome: Guest

log in

Central Nervous System Schizophrenia

Publication Date March 2008
Publisher Life Science Analytics
Product Type Report
Pages 176
ISBN Number not applicable
Product Code LSA02325
Price

£800.00
approximately: $1,169 | €877

PDFBuy Now
PRINT £850 ($1,242 | €932)Buy Now
Order above formats by FAXOrder by FAX

Summary

Life Science Analytics', Central Nervous System Memory Impairment contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

  • Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
  • Keep track of your competitors and partners by better understanding their product pipeline.
  • Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
  • Maintain a critical competitive advantage.

Content

  • Memory Impairment Pipeline Overview
    • % of Projects (by Phase of Development)
    • No. of Projects by Phase of Development
    • Marketed Products vs. Pipeline Products
  • Company Overview - Pipeline Projects
    • Company Overview - Pipeline Projects
    • Top Companies in late stage Memory Impairment Projects
    • Allon Therapeutics Inc.
    • Accera, Inc.
    • AstraZeneca Plc
    • Amarin Corporation plc
    • Eli Lilly & Co
    • Cephalon Inc
    • Inflazyme Pharmaceuticals Ltd.
    • Helicon Therapeutics, Inc
    • Lexicon Pharmaceuticals, Inc
    • Ipsen Ltd
    • Pharmos Corporation
    • Memory Pharmaceuticals Corp
    • SERVIER
    • Saegis Pharmaceuticals, Inc.
    • Targacept Inc
    • Symphony Icon, Inc.
    • Top Companies in early stage Memory Impairment Projects
    • Amarin Corporation plc
    • Abbott Laboratories
    • Avera Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • DrugAbuse Sciences, Inc.
    • BTG plc
    • EPIX Pharmaceuticals Inc
    • Eli Lilly & Co
    • Helicon Therapeutics, Inc
    • Esteve
    • Mimetogen Pharmaceuticals Inc.
    • Krenitsky Pharmaceuticals Inc.
    • Pharmaxon
    • Nyxis Neurotherapies, Inc.
    • Roche Holdings Ltd
    • Proteome Systems Limited
    • Targacept Inc
    • Suven Life Sciences Limited
    • Xytis, Inc.
    • Vasogen Inc
  • Full Pipeline View
    • Pre Clinical Pipeline View
    • Phase I Pipeline View
    • Phase II Pipeline View
    • Phase III Pipeline View
    • on the Market Pipeline View
    • Discovery/Development Pipeline View